Abstract
Investigation of human UDP-glucuronosyltransferase (UGT) isoforms has been limited by a lack of specific substrate probes. In this study serotonin was evaluated for use as a probe substrate for human UGT1A6 using recombinant human UGTs and tissue microsomes. Of the 10 commercially available recombinant UGT isoforms, only UGT1A6 catalyzed serotonin glucuronidation. Serotonin-UGT activity at 40 mM serotonin concentration varied more than 40-fold among human livers (n = 54), ranging from 0.77 to 32.9 nmol/min/mg of protein with a median activity of 7.1 nmol/min/mg of protein. Serotonin-UGT activity kinetics of representative human liver microsomes (n = 7) and pooled human kidney, intestinal and lung microsomes and recombinant human UGT1A6 typically followed one enzyme Michaelis-Menten kinetics. Serotonin glucuronidation activity in these human liver microsomes had widely varying Vmax values ranging from 0.62 to 51.3 nmol/min/mg of protein but very similar apparentKm values ranging from 5.2 to 8.8 mM. Pooled human kidney, intestine, and lung microsomes hadVmax values (mean ± standard error of the estimates) of 8.8 ± 0.4, 0.22 ± 0.00, and 0.03 ± 0.00 nmol/min/mg of protein (respectively) and apparentKm values of 6.5 ± 0.9, 12.4 ± 2.0, and 4.9 ± 3.3 mM (respectively). In comparison, recombinant UGT1A6 had a Vmax of 4.5 ± 0.1 nmol/min/mg of protein and an apparent Km of 5.0 ± 0.4 mM. A highly significant correlation was found between immunoreactive UGT1A6 protein content and serotonin-UGT activity measured at 4 mM serotonin concentration in human liver microsomes (Rs = 0.769; P < 0.001) (n = 52). In conclusion, these results indicate that serotonin is a highly selective in vitro probe substrate for human UGT1A6.
Footnotes
- Abbreviations used are::
- UGT
- UDP-glucuronosyltransferase
- UDPGA
- UDP-glucuronic acid
- HLM
- human liver microsomes
- HPLC
- high performance liquid chromatography
- AZT
- 3′-azido-2′,3′-dideoxythymidine
- Rs
- Spearman correlation coefficient
- Received August 13, 2002.
- Accepted October 15, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|